{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:54:15Z","timestamp":1790621655574,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SKY2023009"],"award-info":[{"award-number":["SKY2023009"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["GZC20231891"],"award-info":[{"award-number":["GZC20231891"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20241793"],"award-info":[{"award-number":["BK20241793"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473045"],"award-info":[{"award-number":["82473045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114345","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T05:50:53Z","timestamp":1761025853000},"page":"114345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer"],"prefix":"10.1016","volume":"388","author":[{"given":"Huan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingchuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114345_bb0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.jconrel.2025.114345_bb0010","doi-asserted-by":"crossref","first-page":"l1049","DOI":"10.1136\/bmj.l1049","article-title":"Lung cancer: diagnosis and management: summary of updated NICE guidance","author":"Maconachie","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2025.114345_bb0015","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.3390\/ijms23169391","article-title":"KRAS-mutant non-small-cell lung cancer: from past efforts to future challenges","volume":"23","author":"Ceddia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114345_bb0020","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41388-018-0479-6","article-title":"mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.114345_bb0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fonc.2019.00953","article-title":"New horizons in KRAS-mutant lung cancer: dawn after darkness","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0030","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114345_bb0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114345_bb0040","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","article-title":"Mechanisms of response and tolerance to active RAS inhibition in KRAS -mutant non\u2013small cell lung cancer","volume":"14","author":"Araujo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2025.114345_bb0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.114345_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.trecan.2022.10.001","article-title":"Precision oncology provides opportunities for targeting KRAS-inhibitor resistance","volume":"9","author":"Sattler","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2025.114345_bb0055","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS -G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.jconrel.2025.114345_bb0060","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114345_bb0065","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114345_bb0070","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","article-title":"Feedback activation of EGFR\/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer","volume":"42","author":"Feng","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.114345_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103417","article-title":"Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy","volume":"164","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0080","article-title":"Advances in systemic therapy for non-small cell lung cancer","volume":"n2363","author":"Miller","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2025.114345_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114345_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1039\/D0NH00605J","article-title":"Targeted liposomal drug delivery: a nanoscience and biophysical perspective","volume":"6","author":"Liu","year":"2021","journal-title":"Nanoscale Horiz."},{"key":"10.1016\/j.jconrel.2025.114345_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0100","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.3390\/ijms20225701","article-title":"Current approaches in NSCLC targeting K-RAS and EGFR","volume":"20","author":"Aran","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114345_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS219","article-title":"A phase 1b\/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC)","volume":"40","author":"Shergill","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41698-022-00329-w","article-title":"Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP","volume":"6","author":"McFall","year":"2022","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-025-02274-z","article-title":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","volume":"10","author":"Ruan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.114345_bb0120","doi-asserted-by":"crossref","first-page":"1380584","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0125","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2025.114345_bb0130","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/ijms23137213","article-title":"The therapeutic potential of the restoration of the p53 protein family members in the EGFR-mutated lung cancer","volume":"23","author":"Fregni","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114345_bb0135","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41467-022-29154-2","article-title":"The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective","volume":"13","author":"Ahmadi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114345_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.05.016","article-title":"A first-in-class EGFR-directed KRAS G12V selective inhibitor","author":"Stanland","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.114345_bb0145","doi-asserted-by":"crossref","first-page":"1509319","DOI":"10.3389\/fphar.2024.1509319","article-title":"Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS\/MS","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2014.01.048","article-title":"Capillary electrophoresis-based assessment of nanobody affinity and purity","volume":"818","author":"Haselberg","year":"2014","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jconrel.2025.114345_bb0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2011.01.015","article-title":"Nanobody \u2014 shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting","volume":"151","author":"Talelli","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114345_bb0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","article-title":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells","volume":"165","author":"Altintas","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114345_bb0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2025.114345_bb0170","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2025.114345_bb0175","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","article-title":"The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer","volume":"84","author":"Kumarasamy","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114345_bb0180","article-title":"With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors","volume":"4","author":"Mainardi","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2025.114345_bb0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.21147\/j.issn.1000-9604.2024.04.06","article-title":"& Cancer Center, the First Hospital of Jilin University, Changchun 130021, China. Immune status and combined immunotherapy progression in kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors","volume":"36","author":"He","year":"2024","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114345_bb0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/onc.2010.430","article-title":"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab","volume":"30","author":"Dunn","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2025.114345_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114345_bb0200","doi-asserted-by":"crossref","first-page":"2250024","DOI":"10.1002\/eji.202250024","article-title":"A few good reasons to use nanobodies for cancer treatment","volume":"53","author":"Jumapili","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0205","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev-immunol-042617-053327","article-title":"Exploiting nanobodies\u2019 singular traits","volume":"36","author":"Ingram","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0210","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jtho.2019.01.011","article-title":"Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Jeanson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2025.114345_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-021-00733-y","article-title":"Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer","volume":"19","author":"Hashimoto","year":"2021","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.jconrel.2025.114345_bb0220","doi-asserted-by":"crossref","first-page":"2312197","DOI":"10.1002\/adfm.202312197","article-title":"Simultaneous modulation of hypoxia and metabolism in glioblastoma for enhanced radio-immunotherapy","volume":"34","author":"Xie","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.114345_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122202","article-title":"Liposome-anchored mesenchymal stem cells for radiation pneumonia\/fibrosis treatment","volume":"300","author":"Zhou","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114345_bb0230","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:02:27Z","timestamp":1769868147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"alternative-id":["S0168365925009599"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114345","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114345"}}